REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients (REVERT)
Sponsor: University of Rome Tor Vergata
Listed as NCT05396807, this NA trial focuses on Metastatic Colon Cancer and remains completed. Sponsored by University of Rome Tor Vergata, it has been updated 9 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Dec 2024 — Sep 2025 [monthly]
Completed NA
Status: Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jun 2024 — Jul 2024 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Jan 2024 — Jun 2024 [monthly]
Recruiting NA
-
Apr 2023 — Jan 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Apr 2023 [monthly]
Not Yet Recruiting NA
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Rome Tor Vergata
For direct contact, visit the study record on ClinicalTrials.gov .